Association between the cilioretinal artery and choroidal neovascularization in age-related macular degeneration a secondary analysis from the age-related eye disease study

Kiersten Snyder, Amirfarbod Yazdanyar, Aditi Mahajan, Glenn C Yiu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

IMPORTANCE A hemodynamic role in the pathogenesis of age-related macular degeneration (AMD) has been proposed, but to our knowledge, an association between retinal vasculature and late AMD has not been investigated. OBJECTIVE To determine whether the presence and location of a cilioretinal artery may be associated with the risk of late AMD in the Age-Related Eye Disease Study (AREDS). DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of prospective, randomized clinical trial data from 3647 AREDS participants. Fundus photographs of AREDS participants were reviewed by 2 masked graders for the presence or absence of a cilioretinal artery and whether any branch extended within 500 μm of the central macula. Multivariate regressions were used to determine the association of the cilioretinal artery and vessel location, adjusted for age, sex, and smoking status, with the prevalence of choroidal neovascularization (CNV) or central geographic atrophy (CGA) and AMD severity score for eyes at randomization and progression at 5 years. MAIN OUTCOMES AND MEASURES Association of cilioretinal artery with prevalence and 5-year incidence of CNV or CGA. RESULTS Among AREDS participants analyzed, mean (SD) age was 69.0 (5.0) years, with 56.3%female, 46.6%former smokers, and 6.9% current smokers. A total of 26.9% of patients had a cilioretinal artery in 1 eye, and 8.4%had the vessel bilaterally. At randomization, eyes with a cilioretinal artery had a lower prevalence of CNV (5.0% vs 7.6%; OR, 0.66; 95%CI, 0.51-0.85; P = .001) but no difference in CGA (1.1% vs 0.8%; OR, 1.33; 95% CI, 0.76-2.32; P = .31). In eyes without late AMD, those with a cilioretinal artery also had a lower mean (SD) AMD severity score (3.00 [2.35] vs 3.19 [2.40]; P = .02). At 5 years, eyes at risk with a cilioretinal artery had lower rates of progression to CNV (4.1% vs 5.5%; OR, 0.75; 95%CI, 0.56-1.00; P = .05) but no difference in developing CGA (2.2%vs 2.7%; OR, 0.83; 95%CI, 0.56-1.23; P = .35) or change in AMD severity score (0.65 [1.55] vs 0.73 [1.70]; P = .11). In patients with a unilateral cilioretinal artery, eyes with the vessel showed a lower prevalence of CNV than fellow eyes (4.7%vs 7.2%; P = .01). CONCLUSIONS AND RELEVANCE The presence of a cilioretinal artery is associated with a lower risk of developing CNV, but not CGA, suggesting a possible retinal hemodynamic contribution to the pathogenesis of neovascular AMD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00000145

Original languageEnglish (US)
Pages (from-to)1008-1014
Number of pages7
JournalJAMA Ophthalmology
Volume136
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Choroidal Neovascularization
Eye Diseases
Macular Degeneration
Arteries
Geographic Atrophy
Random Allocation
Hemodynamics
Randomized Controlled Trials
Smoking

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Association between the cilioretinal artery and choroidal neovascularization in age-related macular degeneration a secondary analysis from the age-related eye disease study. / Snyder, Kiersten; Yazdanyar, Amirfarbod; Mahajan, Aditi; Yiu, Glenn C.

In: JAMA Ophthalmology, Vol. 136, No. 9, 01.09.2018, p. 1008-1014.

Research output: Contribution to journalArticle

@article{38e986a8d2814d8fb67baebd317f840d,
title = "Association between the cilioretinal artery and choroidal neovascularization in age-related macular degeneration a secondary analysis from the age-related eye disease study",
abstract = "IMPORTANCE A hemodynamic role in the pathogenesis of age-related macular degeneration (AMD) has been proposed, but to our knowledge, an association between retinal vasculature and late AMD has not been investigated. OBJECTIVE To determine whether the presence and location of a cilioretinal artery may be associated with the risk of late AMD in the Age-Related Eye Disease Study (AREDS). DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of prospective, randomized clinical trial data from 3647 AREDS participants. Fundus photographs of AREDS participants were reviewed by 2 masked graders for the presence or absence of a cilioretinal artery and whether any branch extended within 500 μm of the central macula. Multivariate regressions were used to determine the association of the cilioretinal artery and vessel location, adjusted for age, sex, and smoking status, with the prevalence of choroidal neovascularization (CNV) or central geographic atrophy (CGA) and AMD severity score for eyes at randomization and progression at 5 years. MAIN OUTCOMES AND MEASURES Association of cilioretinal artery with prevalence and 5-year incidence of CNV or CGA. RESULTS Among AREDS participants analyzed, mean (SD) age was 69.0 (5.0) years, with 56.3{\%}female, 46.6{\%}former smokers, and 6.9{\%} current smokers. A total of 26.9{\%} of patients had a cilioretinal artery in 1 eye, and 8.4{\%}had the vessel bilaterally. At randomization, eyes with a cilioretinal artery had a lower prevalence of CNV (5.0{\%} vs 7.6{\%}; OR, 0.66; 95{\%}CI, 0.51-0.85; P = .001) but no difference in CGA (1.1{\%} vs 0.8{\%}; OR, 1.33; 95{\%} CI, 0.76-2.32; P = .31). In eyes without late AMD, those with a cilioretinal artery also had a lower mean (SD) AMD severity score (3.00 [2.35] vs 3.19 [2.40]; P = .02). At 5 years, eyes at risk with a cilioretinal artery had lower rates of progression to CNV (4.1{\%} vs 5.5{\%}; OR, 0.75; 95{\%}CI, 0.56-1.00; P = .05) but no difference in developing CGA (2.2{\%}vs 2.7{\%}; OR, 0.83; 95{\%}CI, 0.56-1.23; P = .35) or change in AMD severity score (0.65 [1.55] vs 0.73 [1.70]; P = .11). In patients with a unilateral cilioretinal artery, eyes with the vessel showed a lower prevalence of CNV than fellow eyes (4.7{\%}vs 7.2{\%}; P = .01). CONCLUSIONS AND RELEVANCE The presence of a cilioretinal artery is associated with a lower risk of developing CNV, but not CGA, suggesting a possible retinal hemodynamic contribution to the pathogenesis of neovascular AMD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00000145",
author = "Kiersten Snyder and Amirfarbod Yazdanyar and Aditi Mahajan and Yiu, {Glenn C}",
year = "2018",
month = "9",
day = "1",
doi = "10.1001/jamaophthalmol.2018.2650",
language = "English (US)",
volume = "136",
pages = "1008--1014",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Association between the cilioretinal artery and choroidal neovascularization in age-related macular degeneration a secondary analysis from the age-related eye disease study

AU - Snyder, Kiersten

AU - Yazdanyar, Amirfarbod

AU - Mahajan, Aditi

AU - Yiu, Glenn C

PY - 2018/9/1

Y1 - 2018/9/1

N2 - IMPORTANCE A hemodynamic role in the pathogenesis of age-related macular degeneration (AMD) has been proposed, but to our knowledge, an association between retinal vasculature and late AMD has not been investigated. OBJECTIVE To determine whether the presence and location of a cilioretinal artery may be associated with the risk of late AMD in the Age-Related Eye Disease Study (AREDS). DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of prospective, randomized clinical trial data from 3647 AREDS participants. Fundus photographs of AREDS participants were reviewed by 2 masked graders for the presence or absence of a cilioretinal artery and whether any branch extended within 500 μm of the central macula. Multivariate regressions were used to determine the association of the cilioretinal artery and vessel location, adjusted for age, sex, and smoking status, with the prevalence of choroidal neovascularization (CNV) or central geographic atrophy (CGA) and AMD severity score for eyes at randomization and progression at 5 years. MAIN OUTCOMES AND MEASURES Association of cilioretinal artery with prevalence and 5-year incidence of CNV or CGA. RESULTS Among AREDS participants analyzed, mean (SD) age was 69.0 (5.0) years, with 56.3%female, 46.6%former smokers, and 6.9% current smokers. A total of 26.9% of patients had a cilioretinal artery in 1 eye, and 8.4%had the vessel bilaterally. At randomization, eyes with a cilioretinal artery had a lower prevalence of CNV (5.0% vs 7.6%; OR, 0.66; 95%CI, 0.51-0.85; P = .001) but no difference in CGA (1.1% vs 0.8%; OR, 1.33; 95% CI, 0.76-2.32; P = .31). In eyes without late AMD, those with a cilioretinal artery also had a lower mean (SD) AMD severity score (3.00 [2.35] vs 3.19 [2.40]; P = .02). At 5 years, eyes at risk with a cilioretinal artery had lower rates of progression to CNV (4.1% vs 5.5%; OR, 0.75; 95%CI, 0.56-1.00; P = .05) but no difference in developing CGA (2.2%vs 2.7%; OR, 0.83; 95%CI, 0.56-1.23; P = .35) or change in AMD severity score (0.65 [1.55] vs 0.73 [1.70]; P = .11). In patients with a unilateral cilioretinal artery, eyes with the vessel showed a lower prevalence of CNV than fellow eyes (4.7%vs 7.2%; P = .01). CONCLUSIONS AND RELEVANCE The presence of a cilioretinal artery is associated with a lower risk of developing CNV, but not CGA, suggesting a possible retinal hemodynamic contribution to the pathogenesis of neovascular AMD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00000145

AB - IMPORTANCE A hemodynamic role in the pathogenesis of age-related macular degeneration (AMD) has been proposed, but to our knowledge, an association between retinal vasculature and late AMD has not been investigated. OBJECTIVE To determine whether the presence and location of a cilioretinal artery may be associated with the risk of late AMD in the Age-Related Eye Disease Study (AREDS). DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of prospective, randomized clinical trial data from 3647 AREDS participants. Fundus photographs of AREDS participants were reviewed by 2 masked graders for the presence or absence of a cilioretinal artery and whether any branch extended within 500 μm of the central macula. Multivariate regressions were used to determine the association of the cilioretinal artery and vessel location, adjusted for age, sex, and smoking status, with the prevalence of choroidal neovascularization (CNV) or central geographic atrophy (CGA) and AMD severity score for eyes at randomization and progression at 5 years. MAIN OUTCOMES AND MEASURES Association of cilioretinal artery with prevalence and 5-year incidence of CNV or CGA. RESULTS Among AREDS participants analyzed, mean (SD) age was 69.0 (5.0) years, with 56.3%female, 46.6%former smokers, and 6.9% current smokers. A total of 26.9% of patients had a cilioretinal artery in 1 eye, and 8.4%had the vessel bilaterally. At randomization, eyes with a cilioretinal artery had a lower prevalence of CNV (5.0% vs 7.6%; OR, 0.66; 95%CI, 0.51-0.85; P = .001) but no difference in CGA (1.1% vs 0.8%; OR, 1.33; 95% CI, 0.76-2.32; P = .31). In eyes without late AMD, those with a cilioretinal artery also had a lower mean (SD) AMD severity score (3.00 [2.35] vs 3.19 [2.40]; P = .02). At 5 years, eyes at risk with a cilioretinal artery had lower rates of progression to CNV (4.1% vs 5.5%; OR, 0.75; 95%CI, 0.56-1.00; P = .05) but no difference in developing CGA (2.2%vs 2.7%; OR, 0.83; 95%CI, 0.56-1.23; P = .35) or change in AMD severity score (0.65 [1.55] vs 0.73 [1.70]; P = .11). In patients with a unilateral cilioretinal artery, eyes with the vessel showed a lower prevalence of CNV than fellow eyes (4.7%vs 7.2%; P = .01). CONCLUSIONS AND RELEVANCE The presence of a cilioretinal artery is associated with a lower risk of developing CNV, but not CGA, suggesting a possible retinal hemodynamic contribution to the pathogenesis of neovascular AMD. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00000145

UR - http://www.scopus.com/inward/record.url?scp=85053531889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053531889&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2018.2650

DO - 10.1001/jamaophthalmol.2018.2650

M3 - Article

C2 - 29978186

AN - SCOPUS:85053531889

VL - 136

SP - 1008

EP - 1014

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -